ORABLOC Drug Patent Profile

When do Orabloc patents expire, and what generic alternatives are available?

Orabloc is a drug marketed by Pierrel and is included in one NDA.

The generic ingredient in ORABLOC is articaine hydrochloride; epinephrine bitartrate. There is one drug master file entry for this compound. Twelve suppliers are listed for this compound. Additional details are available on the articaine hydrochloride; epinephrine bitartrate profile page.

Summary for ORABLOC

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	4
Raw Ingredient (Bulk) Api Vendors:	58
Clinical Trials:	1
Patent Applications:	3,485
What excipients (inactive ingredients) are in ORABLOC?	ORABLOC excipients list
DailyMed Link:	ORABLOC at DailyMed

Recent Clinical Trials for ORABLOC

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
National Taiwan University Hospital	N/A

See all ORABLOC clinical trials

Pharmacology for ORABLOC

Drug Class	Amide Local Anesthetic Catecholamine alpha-Adrenergic Agonist beta-Adrenergic Agonist
Mechanism of Action	Adrenergic alpha-Agonists Adrenergic beta-Agonists
Physiological Effect	Local Anesthesia

US Patents and Regulatory Information for ORABLOC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466-001	Feb 26, 2010		RX	Yes	No
Pierrel	ORABLOC	articaine hydrochloride; epinephrine bitartrate	INJECTABLE;INJECTION	022466-002	Feb 26, 2010		RX	Yes	Yes

ORABLOC Market Dynamics and Financial Trajectory

Last updated: August 25, 2026

ORABLOC is a branded dental local anesthetic containing articaine hydrochloride and epinephrine. Its market position is based on clinical familiarity, dental-distributor access, and brand recognition rather than broad patent exclusivity. The product competes in a mature market against generic articaine, Septodont’s Septocaine, and other injectable dental anesthetics. Product-level revenue is not separately disclosed by Pierrel, so ORABLOC’s financial trajectory must be assessed through company filings, market structure, regulatory status, and competitive indicators rather than audited standalone sales.

What is ORABLOC and who manufactures it?

ORABLOC is a sterile injectable dental anesthetic supplied in single-use dental cartridges. Its active ingredient is articaine hydrochloride combined with epinephrine, generally in two common concentrations:

Product	Articaine concentration	Epinephrine concentration	Primary use
ORABLOC 4% with 1:100,000 epinephrine	40 mg/mL	0.01 mg/mL	Dental infiltration and nerve-block anesthesia
ORABLOC 4% with 1:200,000 epinephrine	40 mg/mL	0.005 mg/mL	Dental anesthesia where lower vasoconstrictor exposure is preferred

Pierrel S.p.A., an Italian pharmaceutical company, is associated with the development and commercial supply of ORABLOC. The product was approved by the U.S. Food and Drug Administration in 2010 under New Drug Application No. 022466. U.S. commercial distribution has involved dental-pharmaceutical channels and dental-product distributors, including Henry Schein-related distribution arrangements in the U.S. market.[1][2]

ORABLOC is a prescription product used primarily by dentists and oral surgeons. Its demand is linked to procedure volume, dental-office inventory practices, distributor contracts, reimbursement conditions, and dentist preference for articaine-based anesthesia.

What is the FDA regulatory status of ORABLOC?

ORABLOC is an FDA-approved prescription local anesthetic. It is not a biologic and has no biosimilar pathway. Any competitive entry would proceed through the abbreviated new drug application pathway for a pharmaceutically equivalent generic, subject to FDA requirements on quality, labeling, manufacturing, and drug-device packaging where applicable.[1]

FDA and regulatory milestones

Milestone	Status
Active ingredient	Articaine hydrochloride with epinephrine
Dosage form	Injectable dental cartridge
FDA pathway	NDA approval for ORABLOC; potential ANDA pathway for generics
FDA approval	2010
Therapeutic category	Dental local anesthetic
Biologic exclusivity	Not applicable
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No publicly established product-specific period identified
Regulatory complexity	Moderate, because sterile manufacturing, cartridge filling, packaging, and quality controls are required

The product’s FDA approval does not create durable market exclusivity by itself. Articaine is a well-established active ingredient, and its clinical use predates ORABLOC by decades in international markets.

When does ORABLOC lose exclusivity?

ORABLOC’s principal U.S. market exclusivity has already expired or is no longer commercially meaningful. The product was approved in 2010, and any standard five-year new chemical entity exclusivity would have ended in 2015 if applicable. Any three-year approval-related exclusivity for new clinical investigations would also have expired no later than 2013, absent a later qualifying supplement.[1]

There is no known long-duration patent barrier comparable to the patent estates protecting newer specialty drugs, biologics, or controlled-release formulations. The commercial protection for ORABLOC is therefore based mainly on:

• Brand familiarity among dental professionals.
• Distributor and wholesaler access.
• Manufacturing quality and supply reliability.
• Dental-cartridge production capacity.
• Regulatory history.
• Contracting and purchasing relationships.
• Switching costs at the dental-office level.

What patents protect ORABLOC?

Publicly visible product information does not indicate a material, unexpired U.S. patent estate that protects ORABLOC’s active ingredient. Articaine hydrochloride and epinephrine are established compounds. The primary product configuration is a conventional sterile injectable dental formulation rather than a new molecular entity.

Potentially relevant intellectual-property areas include:

1. Formulation composition and stability.
2. Cartridge construction and container-closure systems.
3. Manufacturing and filling methods.
4. Packaging and labeling.
5. Device compatibility and delivery systems.

These categories may support operational protection, but they do not necessarily block an ANDA for a pharmaceutically equivalent generic. A competitor could design around nonessential packaging or process claims while relying on the same active ingredients.

How large is the ORABLOC market?

ORABLOC competes within the broader dental local-anesthetic market, which includes articaine, lidocaine, mepivacaine, prilocaine, and bupivacaine products. The market is mature and procedure-driven rather than innovation-driven.

Articaine has a strong position in many dental markets because of its potency, tissue diffusion, and suitability for infiltration anesthesia. In the U.S., Septocaine has historically been the leading branded articaine product. ORABLOC is a smaller challenger with a similar active ingredient and dosage profile.

Competitive positioning

Product	Active ingredient	Typical position
ORABLOC	Articaine plus epinephrine	Branded articaine competitor
Septocaine	Articaine plus epinephrine	Established leading articaine brand
Generic articaine products	Articaine plus epinephrine	Price-focused alternatives
Lidocaine dental products	Lidocaine plus epinephrine	Broad incumbent alternative
Mepivacaine products	Mepivacaine, with or without vasoconstrictor	Alternative for selected patients and procedures
Prilocaine products	Prilocaine plus felypressin or other combinations by market	International and specialty alternative

ORABLOC’s addressable market is constrained by the fact that dental offices can substitute among several local anesthetic products. The product does not have a captive indication or a proprietary delivery system that would materially limit switching.

What drives ORABLOC demand?

Demand is tied to dental procedure volume rather than chronic treatment prevalence. Key demand drivers include:

• Number of dental visits and invasive procedures.
• Growth in restorative dentistry, endodontics, oral surgery, and implant procedures.
• Dentist adoption of articaine for infiltration anesthesia.
• Expansion of dental service organizations.
• Dental-office preference for standardized cartridge formats.
• Availability through national distributors.
• Product supply continuity.

The principal demand risk is economic sensitivity. Dental care is partly paid directly by patients, and elective procedures can be delayed during periods of reduced consumer spending. Conversely, aging populations and higher rates of restorative and implant dentistry can support long-term procedure growth.

ORABLOC also benefits from repeat professional use. Once a dental office standardizes a cartridge format, switching may require changes to purchasing systems, staff familiarity, inventory practices, and clinician preference. These barriers are modest but commercially relevant.

How does ORABLOC compare with Septocaine and generic articaine?

ORABLOC and Septocaine have similar clinical positioning because both use articaine hydrochloride with epinephrine in dental cartridges. The main competitive variables are price, supply, distributor availability, dentist familiarity, and perceived product quality.

Factor	ORABLOC	Septocaine	Generic articaine
Active ingredient	Articaine hydrochloride	Articaine hydrochloride	Articaine hydrochloride
Brand status	Branded	Branded	Generic
Patent dependence	Low	Low to moderate, depending on product-specific claims	Low
Price position	Typically below or competitive with leading brand	Often premium branded position	Lowest-cost segment
Clinical differentiation	Limited	Limited	Limited
Distributor leverage	Important	Strong established relationships	Increasingly important
Switching risk	Moderate	Moderate	High if price pressure increases

ORABLOC’s ability to gain share depends less on clinical differentiation than on delivered cost and reliable availability. A branded product can retain share if it offers stable supply, favorable contracting, and adequate dentist support. Generic entry or aggressive pricing can pressure margins quickly because the underlying product is relatively standardized.

Which companies challenge ORABLOC?

The competitive set includes:

• Septodont, through Septocaine and related articaine products.
• Manufacturers of generic articaine hydrochloride with epinephrine.
• Dentsply Sirona and other dental suppliers competing for dental-office purchasing budgets.
• Manufacturers of lidocaine, mepivacaine, and other injectable dental anesthetics.
• Private-label or distributor-branded products where available.

The main strategic threat is not a single patent challenger. It is substitution by a lower-priced equivalent product. Large dental distributors can influence market share through formulary placement, purchasing contracts, rebates, private-label offerings, and inventory prioritization.

Are there Paragraph IV challenges to ORABLOC?

No material, publicly established Paragraph IV litigation campaign is associated with ORABLOC’s core product based on the publicly available regulatory and litigation record through 2024.

That outcome is consistent with the product’s age and limited apparent patent protection. A generic applicant would have little reason to challenge a strong patent estate if the relevant patents have expired or do not materially cover the active formulation. Competitive entry would more likely involve ordinary ANDA filing and approval risks, including bioequivalence where applicable, manufacturing validation, sterile-product quality, and FDA review of the proposed labeling.

What formulation patents protect ORABLOC?

No widely recognized unexpired formulation patent is publicly identified as the primary commercial barrier for ORABLOC. The standard formulation combines articaine hydrochloride, epinephrine, excipients, and a sterile aqueous vehicle in a dental cartridge.

Potential formulation vulnerabilities include:

• Chemical stability of epinephrine.
• Sterility assurance.
• pH control.
• Container-closure integrity.
• Cartridge compatibility.
• Shelf-life validation.
• Leachables and extractables.
• Manufacturing consistency at commercial scale.

These are important regulatory and manufacturing requirements. They are not equivalent to patent exclusivity. A competitor can face meaningful technical execution risk without being legally excluded from the market.

What manufacturing barriers affect ORABLOC?

Manufacturing is a more significant barrier than intellectual property. ORABLOC requires sterile injectable production and specialized dental-cartridge filling. Relevant capabilities include:

• Sterile compounding and filling.
• High-volume cartridge production.
• Validated sterilization processes.
• Epinephrine stability control.
• Inspection for container defects.
• Compliance with current good manufacturing practices.
• Consistent supply of dental cartridges and packaging components.

A new entrant must secure validated production capacity and pass FDA inspection. Quality failures, contamination events, particulate defects, or supply interruptions can materially affect dentist confidence because local anesthetics are used in routine procedures where product substitution is operationally easy.

What is the financial trajectory of ORABLOC?

Pierrel does not publicly report ORABLOC revenue as a separate audited line item. Its financial disclosures generally report consolidated company performance and business segments rather than a complete ORABLOC-specific income statement. As a result, revenue, gross margin, market share, and operating profit for ORABLOC cannot be stated as independently verified product figures.

The financial trajectory is best characterized as follows:

Period	Financial interpretation
2010-2014	Initial commercialization and market-building after U.S. approval
2015-2019	Mature branded competition against Septocaine and established anesthetic products
2020	Exposure to dental-office closures and deferred procedures during the COVID-19 disruption
2021-2023	Recovery linked to reopening, procedure normalization, and dental supply demand
2024 onward	Mature-market growth dependent on procedure volume, pricing, distribution, and product availability

ORABLOC likely contributes strategic value as part of Pierrel’s dental-pharmaceutical portfolio, but public filings do not support a defensible standalone revenue forecast. The product’s economic profile is more consistent with a mature branded injectable than with a high-margin, patent-protected specialty medicine.

Revenue exposure

ORABLOC’s revenue exposure is concentrated in:

• U.S. dental demand.
• Distributor purchasing schedules.
• Articaine category growth.
• Price competition.
• Manufacturing capacity.
• Product continuity.

The largest downside risk is margin compression from generic or distributor-led price competition. The largest upside opportunity is share gain within the articaine category through improved distribution, competitive pricing, and reliable supply.

What is the generic launch risk for ORABLOC?

Generic launch risk is high in principle because:

1. The active ingredient is established.
2. The product is a conventional injectable formulation.
3. Major regulatory exclusivity periods have expired.
4. Clinical substitution is relatively straightforward.
5. Dentists and distributors can compare products primarily on price and supply.

The practical timing of generic entry would still depend on FDA approval, manufacturing readiness, distributor access, and commercial economics. A generic entrant must achieve sufficient scale to justify sterile production, cartridge tooling, quality testing, and sales-channel costs.

A likely launch scenario is gradual price erosion rather than immediate market displacement. Dental offices may retain ORABLOC if supply is dependable and the price differential is modest. Large dental organizations and distributors are more likely to switch rapidly when contracts create material savings.

What litigation and settlement agreements affect ORABLOC?

No significant publicly documented patent litigation or settlement agreement is identified as a major current constraint on ORABLOC commercialization through 2024. The legal risk profile is therefore lower than for products protected by active composition-of-matter, formulation, or method-of-use patents.

Potential future disputes would more likely involve:

• ANDA patent certifications.
• Product labeling.
• Trade dress or trademark rights.
• Distributor agreements.
• Manufacturing quality claims.
• Supply and contract disputes.

ORABLOC’s brand protection is distinct from patent protection. Trademark rights can limit confusingly similar branding but do not prevent competitors from selling equivalent articaine products under different names.

What is the geographic coverage of ORABLOC?

ORABLOC’s strongest identifiable commercial relevance is in the United States, where FDA approval and dental-distribution relationships support market access. Pierrel has broader international dental-pharmaceutical activities, but product availability and branding vary by country.

Geographic performance depends on:

• National registration.
• Local distributor rights.
• Dental-cartridge standards.
• Pricing and reimbursement.
• Epinephrine labeling requirements.
• Local competition from Septocaine and other articaine products.
• Regulatory requirements for sterile injectables.

The U.S. market is commercially important because of its large dental-services sector, but it is also highly competitive and exposed to branded and generic substitution.

How strong is the ORABLOC patent estate?

ORABLOC has a weak patent-based moat and a moderate operational moat.

Protection category	Assessment
Active-ingredient patent	Weak or expired
FDA regulatory exclusivity	Expired
Formulation patents	No material unexpired barrier publicly established
Method-of-use patents	Limited relevance
Trademark and brand	Moderate
Distribution relationships	Moderate
Manufacturing capability	Moderate to strong
Dentist switching costs	Moderate
Generic-entry resistance	Low

The product can remain commercially viable without strong patents because dental local anesthetics are purchased through recurring professional channels. Its durability depends on execution, not legal exclusivity.

Key Takeaways

• ORABLOC is a branded articaine hydrochloride and epinephrine dental anesthetic associated with Pierrel.
• FDA approval dates to 2010, and regulatory exclusivity is no longer a meaningful protection.
• No major unexpired patent barrier or Paragraph IV litigation campaign is publicly established.
• Septocaine and generic articaine are the principal competitive threats.
• Product demand follows dental procedure volume and distributor access.
• Sterile cartridge manufacturing is a more important barrier than patent rights.
• Pierrel does not separately disclose ORABLOC revenue, preventing a verified product-level financial forecast.
• The financial outlook is mature and execution-driven, with upside from share gains and downside from price erosion, generic entry, and supply disruption.

FAQs About ORABLOC Market and Financial Prospects

Is ORABLOC the same as articaine?

ORABLOC is a branded product containing articaine hydrochloride with epinephrine. Articaine is the active ingredient, while ORABLOC is the commercial brand.

Can dentists substitute generic articaine for ORABLOC?

Subject to applicable prescribing, procurement, and institutional rules, generic articaine products may compete directly with ORABLOC when they have equivalent active ingredients, dosage strengths, and approved indications.

Does ORABLOC have biologic or biosimilar competition?

No. ORABLOC is a small-molecule injectable dental anesthetic, not a biologic. Biosimilar rules do not apply.

Is ORABLOC protected by a composition-of-matter patent?

Articaine is an established active ingredient, and no material unexpired composition-of-matter patent is publicly identified as protecting ORABLOC’s current commercial product.

What would increase ORABLOC’s commercial value?

Improved dental-distributor coverage, reliable cartridge supply, favorable purchasing contracts, international registrations, and differentiated packaging or delivery systems would have greater commercial impact than additional clinical claims for the existing formulation.

References

1. U.S. Food and Drug Administration. (2010). ORABLOC: Articaine hydrochloride and epinephrine injection, prescribing information. FDA Drugs@FDA.

2. Pierrel S.p.A. (2023). Annual report and financial statements for the year ended December 31, 2023. Pierrel S.p.A.

3. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database. FDA.

5. Septodont. (2024). Septocaine articaine hydrochloride and epinephrine injection product information. Septodont.